FDA Determines Regulatory Review Period for ELREXFIO for Patent Extension
May 10, 2025
May 10, 2025
WASHINGTON, May 10 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) has announced its determination regarding the regulatory review period for the human biological product ELREXFIO, which is developed by Pfizer Inc.
The announcement comes after a request by the U.S. Patent and Trademark Office (USPTO) for FDA's assistance in determining the regulatory review period for patent term restoration related to this product. The review per . . .
The announcement comes after a request by the U.S. Patent and Trademark Office (USPTO) for FDA's assistance in determining the regulatory review period for patent term restoration related to this product. The review per . . .